LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | OSI-027 | 10.0 | uM | LJP6 | 3 | E07 | 72 | hr | 1235 | 1704 | 4156 | 0.4100 | 0.1604 |
| MCF7 | XMD11-85h | 10.0 | uM | LJP6 | 1 | P19 | 72 | hr | 1235 | 1760 | 4156 | 0.4235 | 0.1796 |
| MCF7 | XMD11-85h | 10.0 | uM | LJP6 | 2 | P19 | 72 | hr | 1235 | 2043 | 4156 | 0.4916 | 0.2765 |
| MCF7 | XMD11-85h | 10.0 | uM | LJP6 | 3 | P19 | 72 | hr | 1235 | 2146 | 4156 | 0.5163 | 0.3118 |
| MCF7 | HG-6-64-01 | 10.0 | uM | LJP6 | 1 | M01 | 72 | hr | 1235 | 814 | 4156 | 0.1959 | -0.1443 |
| MCF7 | HG-6-64-01 | 10.0 | uM | LJP6 | 2 | M01 | 72 | hr | 1235 | 661 | 4156 | 0.1590 | -0.1967 |
| MCF7 | HG-6-64-01 | 10.0 | uM | LJP6 | 3 | M01 | 72 | hr | 1235 | 630 | 4156 | 0.1516 | -0.2073 |
| MCF7 | WH-4-025 | 10.0 | uM | LJP5 | 1 | O07 | 72 | hr | 1235 | 979 | 4156 | 0.2356 | -0.0878 |
| MCF7 | WH-4-025 | 10.0 | uM | LJP5 | 2 | O07 | 72 | hr | 1235 | 1068 | 4156 | 0.2570 | -0.0573 |
| MCF7 | WH-4-025 | 10.0 | uM | LJP5 | 3 | O07 | 72 | hr | 1235 | 1084 | 4156 | 0.2608 | -0.0518 |
| MCF7 | WZ-4-145 | 10.0 | uM | LJP6 | 1 | J19 | 72 | hr | 1235 | 912 | 4156 | 0.2194 | -0.1107 |
| MCF7 | WZ-4-145 | 10.0 | uM | LJP6 | 2 | J19 | 72 | hr | 1235 | 831 | 4156 | 0.1999 | -0.1385 |
| MCF7 | WZ-4-145 | 10.0 | uM | LJP6 | 3 | J19 | 72 | hr | 1235 | 944 | 4156 | 0.2271 | -0.0998 |
| MCF7 | XMD16-144 | 10.0 | uM | LJP5 | 1 | M07 | 72 | hr | 1235 | 588 | 4156 | 0.1415 | -0.2217 |
| MCF7 | XMD16-144 | 10.0 | uM | LJP5 | 2 | M07 | 72 | hr | 1235 | 849 | 4156 | 0.2043 | -0.1323 |
| MCF7 | XMD16-144 | 10.0 | uM | LJP5 | 3 | M07 | 72 | hr | 1235 | 761 | 4156 | 0.1831 | -0.1624 |
| MCF7 | Brivanib | 10.0 | uM | LJP5 | 1 | P13 | 72 | hr | 1235 | 3241 | 4156 | 0.7798 | 0.6867 |
| MCF7 | Brivanib | 10.0 | uM | LJP5 | 2 | P13 | 72 | hr | 1235 | 3901 | 4156 | 0.9386 | 0.9126 |
| MCF7 | Brivanib | 10.0 | uM | LJP5 | 3 | P13 | 72 | hr | 1235 | 3774 | 4156 | 0.9081 | 0.8692 |
| MCF7 | Buparlisib | 10.0 | uM | LJP5 | 1 | H01 | 72 | hr | 1235 | 845 | 4156 | 0.2033 | -0.1337 |
| MCF7 | Buparlisib | 10.0 | uM | LJP5 | 2 | H01 | 72 | hr | 1235 | 902 | 4156 | 0.2170 | -0.1141 |
| MCF7 | Buparlisib | 10.0 | uM | LJP5 | 3 | H01 | 72 | hr | 1235 | 874 | 4156 | 0.2103 | -0.1237 |
| MCF7 | BX-912 | 10.0 | uM | LJP5 | 1 | L19 | 72 | hr | 1235 | 1232 | 4156 | 0.2964 | -0.0012 |
| MCF7 | BX-912 | 10.0 | uM | LJP5 | 2 | L19 | 72 | hr | 1235 | 1241 | 4156 | 0.2986 | 0.0019 |
| MCF7 | BX-912 | 10.0 | uM | LJP5 | 3 | L19 | 72 | hr | 1235 | 1370 | 4156 | 0.3296 | 0.0461 |